{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:38:56Z","timestamp":1781264336013,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004252","name":"Qatar University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40261-024-01413-8","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:29:52Z","timestamp":1738254592000},"page":"151-163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Dihydropyrimidine Dehydrogenase Deficiency (DPYD) Genotyping-Guided Fluoropyrimidine-Based Adjuvant Chemotherapy for Breast Cancer. A Cost-Effectiveness Analysis"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4162-8617","authenticated-orcid":false,"given":"Dina","family":"Abushanab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaban","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Abdel-latif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diala Alhaj","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafa","family":"Marridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen","family":"Elazzazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radja","family":"Badji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wadha","family":"Al-Muftah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said I.","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salha","family":"Bujassoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Al-Thani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7791-954X","authenticated-orcid":false,"given":"Daoud","family":"Al-Badriyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moza","family":"Al Hail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"1413_CR1","unstructured":"The Global Cancer Observatory. International Agency for Research on Cancer. 2021. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/634-qatar-fact-sheets.pdf. Accessed 10 Apr 2024."},{"key":"1413_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejca.2018.11.010","volume":"107","author":"LM Henricks","year":"2019","unstructured":"Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, et al. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy. Eur J Cancer. 2019;107:60\u20137.","journal-title":"Eur J Cancer"},{"issue":"5","key":"1413_CR3","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330\u20138.","journal-title":"Nat Rev Cancer"},{"issue":"16","key":"1413_CR4","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","volume":"16","author":"D Meulendijks","year":"2015","unstructured":"Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, Largiad\u00e8r CR, Jennings BA, Marinaki AM, Sanderson JD, Kleibl Z, Kleiblova P, Schwab M, Zanger UM, Palles C, Tomlinson I, Gross E, van Kuilenburg AB, Punt CJ, Koopman M, Beijnen JH, Cats A, Schellens JH. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(16):1639\u201350.","journal-title":"Lancet Oncol"},{"issue":"21","key":"1413_CR5","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","volume":"19","author":"E Van Cutsem","year":"2001","unstructured":"Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(21):4097\u2013106.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"8","key":"1413_CR6","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","volume":"19","author":"PM Hoff","year":"2001","unstructured":"Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(8):2282\u201392.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"3","key":"1413_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","volume":"34","author":"MJ Deenen","year":"2016","unstructured":"Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(3):227\u201334.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"11","key":"1413_CR8","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","volume":"19","author":"LM Henricks","year":"2018","unstructured":"Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018;19(11):1459\u201367.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1413_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1053\/j.seminoncol.2017.02.008","volume":"44","author":"M Boisdron-Celle","year":"2017","unstructured":"Boisdron-Celle M, Capitain O, Faroux R, Borg C, Metges JP, Galais MP, et al. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: assessment of a multiparametric approach. Semin Oncol. 2017;44(1):13\u201323.","journal-title":"Semin Oncol"},{"issue":"3","key":"1413_CR10","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1016\/j.clcc.2022.05.001","volume":"21","author":"GA Brooks","year":"2022","unstructured":"Brooks GA, Tapp S, Daly AT, Busam JA, Tosteson ANA. Cost-effectiveness of DPYD genotyping prior to fluoropyrimidine-based adjuvant chemotherapy for colon cancer. Clin Colorectal Cancer. 2022;21(3):e189\u201395.","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"1413_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2217\/pme-2022-0099","volume":"20","author":"R Koleva-Kolarova","year":"2023","unstructured":"Koleva-Kolarova R, Vellekoop H, Huygens S, Versteegh M, M\u00f6lken MR, Szilberhorn L, et al. Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK. Per Med. 2023;20(4):339\u201355.","journal-title":"Per Med"},{"issue":"1","key":"1413_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41525-022-00281-5","volume":"7","author":"PV Jithesh","year":"2022","unstructured":"Jithesh PV, Abuhaliqa M, Syed N, Ahmed I, El Anbari M, Bastaki K, et al. A population study of clinically actionable genetic variation affecting drug response from the Middle East. npj Genomic Med. 2022;7(1):10.","journal-title":"npj Genomic Med"},{"key":"1413_CR13","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), 2017 [Internet]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_8.5x11.pdf. Accessed 10 Apr 2024"},{"issue":"2","key":"1413_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther. 2018;103(2):210\u20136.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1413_CR15","first-page":"107","volume":"35","author":"M Haacker","year":"2020","unstructured":"Haacker M, Hallett TB, Atun R. On discount rates for economic evaluations in global health. Health Policy Plan. 2020;35(1):107\u201314.","journal-title":"Health Policy Plan"},{"key":"1413_CR16","unstructured":"National Center for Cancer Care and Research. Hamad Medical Corporation. 2024 [Internet]. Available from: https:\/\/hamad.qa\/EN\/Hospitals-and-services\/Physiotherapy\/Facilities\/Pages\/NCCCR.aspx. Accessed 10 Apr 2024."},{"key":"1413_CR17","doi-asserted-by":"crossref","unstructured":"Abushanab D, Al-Badriyeh D, Liew D, Ademi Z. First-line treatment with empagliflozin and metformin combination versus standard care for patients with type 2 diabetes mellitus and cardiovascular disease in qatar. a cost-effectiveness analysis. Curr Probl Cardiol. 2022;47(6):100852.","DOI":"10.1016\/j.cpcardiol.2021.100852"},{"issue":"12","key":"1413_CR18","doi-asserted-by":"publisher","first-page":"101385","DOI":"10.1016\/j.cpcardiol.2022.101385","volume":"47","author":"R Kaddoura","year":"2022","unstructured":"Kaddoura R, Abushanab D, Arabi AR, Al-Yafei SA-S, Al-Badriyeh D. Cost-effectiveness analysis of sacubitril\/valsartan for reducing the use of implantable cardioverter-defibrillator (ICD) and the risk of death in ICD-eligible heart failure patients with reduced ejection fraction. Curr Probl Cardiol. 2022;47(12):101385.","journal-title":"Curr Probl Cardiol"},{"key":"1413_CR19","doi-asserted-by":"crossref","unstructured":"Al-Badriyeh D, Hssain AA, Abushanab D. Cost-Effectiveness analysis of out-of-hospital versus in-hospital extracorporeal cardiopulmonary resuscitation for out-hospital refractory cardiac arrest. Curr Probl Cardiol. 2022;47(12):101387.","DOI":"10.1016\/j.cpcardiol.2022.101387"},{"key":"1413_CR20","unstructured":"Clinical Laboratory Fee Schedule Files. Centers for Medicare & Medicaid Services. 2021. https:\/\/www.cms.gov\/. Accessed 10 Apr 2024."},{"key":"1413_CR21","first-page":"w14626","volume":"148","author":"Z Ademi","year":"2018","unstructured":"Ademi Z, Tomonaga Y, van Stiphout J, Glinz D, Gloy V, Raatz H, et al. Adaptation of cost-effectiveness analyses to a single country: the case of bariatric surgery for obesity and overweight. Swiss Med Wkly. 2018;148:w14626.","journal-title":"Swiss Med Wkly"},{"key":"1413_CR22","unstructured":"Qatar Inflation Rate. 2024. https:\/\/tradingeconomics.com\/qatar\/inflation-cpi. Accessed 10 Apr 2024."},{"issue":"1","key":"1413_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/bmb\/ldq033","volume":"96","author":"SJ Whitehead","year":"2010","unstructured":"Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96(1):5\u201321.","journal-title":"Br Med Bull"},{"issue":"6","key":"1413_CR24","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","volume":"95","author":"A Lloyd","year":"2006","unstructured":"Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95(6):683\u201390.","journal-title":"Br J Cancer"},{"issue":"5","key":"1413_CR25","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1177\/0272989X211065471","volume":"42","author":"MN Kaur","year":"2022","unstructured":"Kaur MN, Yan J, Klassen AF, David JP, Pieris D, Sharma M, et al. A systematic literature review of health utility values in breast cancer. Med Decis Mak an Int J Soc Med Decis Mak. 2022;42(5):704\u201319.","journal-title":"Med Decis Mak an Int J Soc Med Decis Mak."},{"key":"1413_CR26","doi-asserted-by":"crossref","unstructured":"Briggs A, Claxton K, Sculpher M. In: Briggs A, Claxton K, Sculpher M, editors. Decision modeling for health economics evaluation. Oxford: Oxford University Press, 2006.","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"issue":"1","key":"1413_CR27","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/jnci\/dju379","volume":"107","author":"R Manchanda","year":"2015","unstructured":"Manchanda R, Loggenberg K, Sanderson S, Burnell M, Wardle J, Gessler S, et al. Population testing for cancer predisposing BRCA1\/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. J Natl Cancer Inst. 2015;107(1):379.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"1413_CR28","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2217\/pgs-2016-0006","volume":"17","author":"L Cortejoso","year":"2016","unstructured":"Cortejoso L, Garc\u00eda-Gonz\u00e1lez X, Garc\u00eda MI, Garc\u00eda-Alfonso P, Sanjurjo M, L\u00f3pez-Fern\u00e1ndez LA. Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines. Pharmacogenomics. 2016;17(9):979\u201384.","journal-title":"Pharmacogenomics"},{"issue":"1","key":"1413_CR29","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/s12885-023-10857-8","volume":"23","author":"DK Lau","year":"2023","unstructured":"Lau DK, Fong C, Arouri F, Cortez L, Katifi H, Gonzalez-Exposito R, et al. Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre. BMC Cancer. 2023;23(1):380.","journal-title":"BMC Cancer"},{"issue":"1","key":"1413_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13073-024-01354-z","volume":"16","author":"JE Knikman","year":"2024","unstructured":"Knikman JE, Zhai Q, Lunenburg CATC, Henricks LM, B\u00f6hringer S, van der Lee M, et al. Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD. Genome Med. 2024;16(1):101.","journal-title":"Genome Med."},{"issue":"5","key":"1413_CR31","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11739-013-0936-8","volume":"8","author":"E Magnani","year":"2013","unstructured":"Magnani E, Farnetti E, Nicoli D, Casali B, Savoldi L, Focaccetti C, et al. Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule. Intern Emerg Med. 2013;8(5):417\u201323.","journal-title":"Intern Emerg Med"},{"key":"1413_CR32","unstructured":"The Global Cancer Observatory. International Agency for Research on Cancer. 2022. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/634-qatar-fact-sheet.pdf. Accessed 10 Apr 2024."},{"issue":"12","key":"1413_CR33","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/onco.13967","volume":"26","author":"BB Sharma","year":"2021","unstructured":"Sharma BB, Rai K, Blunt H, Zhao W, Tosteson TD, Brooks GA. Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis. Oncologist. 2021;26(12):1008\u201316.","journal-title":"Oncologist"},{"issue":"11","key":"1413_CR34","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/bjc.2017.94","volume":"116","author":"D Meulendijks","year":"2017","unstructured":"Meulendijks D, Henricks LM, Jacobs BAW, Aliev A, Deenen MJ, de Vries N, et al. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer. 2017;116(11):1415\u201324.","journal-title":"Br J Cancer"},{"issue":"4","key":"1413_CR35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/rmir.12195","volume":"24","author":"AER Prince","year":"2021","unstructured":"Prince AER, Uhlmann WR, Suter SM, Scherer AM. Genetic testing and insurance implications: surveying the US general population about discrimination concerns and knowledge of the Genetic Information Nondiscrimination Act (GINA). Risk Manag Insur Rev. 2021;24(4):341\u201365.","journal-title":"Risk Manag Insur Rev."},{"issue":"2","key":"1413_CR36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/00007691-199904000-00002","volume":"21","author":"DR Sohn","year":"1999","unstructured":"Sohn DR, Cho MS, Chung PJ. Dihydropyrimidine dehydrogenase activity in a Korean population. Ther Drug Monit. 1999;21(2):152\u20134.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"1413_CR37","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/clpt.2013.69","volume":"94","author":"SM Offer","year":"2013","unstructured":"Offer SM, Lee AM, Mattison LK, Fossum C, Wegner NJ, Diasio RB. A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity. Clin Pharmacol Ther. 2013;94(1):158\u201366.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1413_CR38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1477-7525-12-58","volume":"12","author":"A Mielck","year":"2014","unstructured":"Mielck A, Vogelmann M, Leidl R. Health-related quality of life and socioeconomic status: inequalities among adults with a chronic disease. Health Qual Life Outcomes. 2014;12(1):58.","journal-title":"Health Qual Life Outcomes"},{"key":"1413_CR39","unstructured":"Quality of Life Index by Country 2024 Mid-Year. https:\/\/www.numbeo.com\/quality-of-life\/rankings_by_country.jsp. Accessed 10 Nov 2024."},{"key":"1413_CR40","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1186\/s12889-023-16171-z","volume":"23","author":"MM Tahoun","year":"2023","unstructured":"Tahoun MM, Ismail HM, Fiidow OA, et al. Quality of life among the Arab population two years after COVID-19 pandemic. BMC Public Health. 2023;23:1268. https:\/\/doi.org\/10.1186\/s12889-023-16171-z.","journal-title":"BMC Public Health"},{"key":"1413_CR41","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13023-022-02343-4","volume":"17","author":"K Bogart","year":"2022","unstructured":"Bogart K, Hemmesch A, Barnes E, et al. Healthcare access, satisfaction, and health-related quality of life among children and adults with rare diseases. Orphanet J Rare Dis. 2022;17:196. https:\/\/doi.org\/10.1186\/s13023-022-02343-4.","journal-title":"Orphanet J Rare Dis"},{"key":"1413_CR42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12939-019-0942-1","volume":"18","author":"S Zhang","year":"2019","unstructured":"Zhang S, Xiang W. Income gradient in health-related quality of life\u2014the role of social networking time. Int J Equity Health. 2019;18:44. https:\/\/doi.org\/10.1186\/s12939-019-0942-1.","journal-title":"Int J Equity Health"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01413-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01413-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01413-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T16:02:21Z","timestamp":1741017741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01413-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1413"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01413-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"assertion":[{"value":"21 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding was provided by the Qatar National Library, Qatar","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no disclosures to declare with regard to the authorship and\/or publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was based on literature and available data. Therefore, no ethics approval is required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Data that are not in the electronic supplementary material are available from the corresponding author upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"DA undertook the study analysis and generation of results and wrote the first draft of the manuscript. DA and DA-B conceived and designed the study methods. All authors contributed to the data collection, result interpretation, and manuscript writing, and read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}